Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel R Denmeade

Showing results (71-80 of 155) with videos related to

Pageof 16
Sort By:
Progress in the Chemistry of Organic Natural Products|April 2, 2021
From Plant to Patient: Thapsigargin, a Tool for Understanding Natural Product Chemistry, Total Syntheses, Biosynthesis, Taxonomy, ATPases, Cell Death, and Drug DevelopmentSøren Brøgger Christensen, Henrik Toft Simonsen, Nikolai Engedal, et al.
Anti-Cancer Agents in Medicinal Chemistry|March 12, 2009
A Trojan horse in drug development: targeting of thapsigargins towards prostate cancer cellsS Brøgger Christensen, Dorthe Mondrup Skytte, Samuel R Denmeade, et al.
Bioorganic & Medicinal Chemistry|July 19, 2015
Design, synthesis and cytotoxicity studies of dithiocarbamate ester derivatives of emetine in prostate cancer cell linesEmmanuel S Akinboye, Zebalda D Bamji, Bernard Kwabi-Addo, et al.
The Prostate|January 24, 2020
Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancerMark C Markowski, Eugene Shenderov, Mario A Eisenberger, et al.
The Journal of Clinical Endocrinology and Metabolism|November 3, 2005
Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancerChristopher J Strock, Jong-In Park, D Marc Rosen, et al.
Biochemistry|December 22, 2007
Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sitesSaurabh Aggarwal, W Nathaniel Brennen, Thomas P Kole, et al.
Molecular Cancer Therapeutics|May 7, 2009
Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cellsDonald J Vander Griend, Lizamma Antony, Susan L Dalrymple, et al.
Clinical Genitourinary Cancer|September 20, 2021
Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen TherapyMark C Markowski, Sushant Kachhap, Angelo M De Marzo, et al.
Immunotherapy|November 5, 2020
Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapyW Nathaniel Brennen, Daniel L J Thorek, Wen Jiang, et al.
The Prostate|March 8, 2012
Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancerJohn T Isaacs, Jason M D'Antonio, Shuangling Chen, et al.
Pageof 16

Showing results (71-80 of 155) with videos related to

Sort By:
Pageof 16
Progress in the Chemistry of Organic Natural Products|April 2, 2021
From Plant to Patient: Thapsigargin, a Tool for Understanding Natural Product Chemistry, Total Syntheses, Biosynthesis, Taxonomy, ATPases, Cell Death, and Drug DevelopmentSøren Brøgger Christensen, Henrik Toft Simonsen, Nikolai Engedal, et al.
Anti-Cancer Agents in Medicinal Chemistry|March 12, 2009
A Trojan horse in drug development: targeting of thapsigargins towards prostate cancer cellsS Brøgger Christensen, Dorthe Mondrup Skytte, Samuel R Denmeade, et al.
Bioorganic & Medicinal Chemistry|July 19, 2015
Design, synthesis and cytotoxicity studies of dithiocarbamate ester derivatives of emetine in prostate cancer cell linesEmmanuel S Akinboye, Zebalda D Bamji, Bernard Kwabi-Addo, et al.
The Prostate|January 24, 2020
Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancerMark C Markowski, Eugene Shenderov, Mario A Eisenberger, et al.
The Journal of Clinical Endocrinology and Metabolism|November 3, 2005
Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancerChristopher J Strock, Jong-In Park, D Marc Rosen, et al.
Biochemistry|December 22, 2007
Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sitesSaurabh Aggarwal, W Nathaniel Brennen, Thomas P Kole, et al.
Molecular Cancer Therapeutics|May 7, 2009
Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cellsDonald J Vander Griend, Lizamma Antony, Susan L Dalrymple, et al.
Clinical Genitourinary Cancer|September 20, 2021
Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen TherapyMark C Markowski, Sushant Kachhap, Angelo M De Marzo, et al.
Immunotherapy|November 5, 2020
Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapyW Nathaniel Brennen, Daniel L J Thorek, Wen Jiang, et al.
The Prostate|March 8, 2012
Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancerJohn T Isaacs, Jason M D'Antonio, Shuangling Chen, et al.
Pageof 16